EarningsQ2 2026 Earnings Report
DE:GON Q2 2026 EPS Results
Actual EPS-€0.02
Consensus EPS>-€0.01
Beat/MissMissed by -<€0.01
One Year Ago EPS-€0.02
DE:GON Q2 2026 Revenue Results
Actual Revenue€51.29M
Expected Revenue€49.35M
Beat/MissBeat by +€1.94M
YoY Revenue Growth+17.22%
Earnings Announcement Details
QuarterQ2 2026
Date08/05/2026
TimeBefore Open
Conference CallWednesday, August 5, 2026
DE:GON Upcoming Earnings
Geron's next earnings date is estimated for November 11, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
DE:GON Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
Overall the call conveyed positive commercial momentum and strengthening scientific evidence for RYTELO and the myelofibrosis program, supported by revenue growth (Q2 $57.5M, +17% YoY, +11% QoQ), expanding accounts and encouraging real-world data. The company also highlighted operational discipline (H1 operating expense down ~4% vs H1 revenue +24%) and a solid cash position ($327M). Counterbalancing these positives are rising gross-to-net deductions (20.7% in Q2 vs 15.3% prior year), a modest quarter-over-quarter cash decline, ongoing investment-driven spending, uncertainty around interim analysis modifications for IMpactMF, and unresolved EU pricing/MFN complexities that could affect ex-U.S. expansion. On balance the favorable revenue, evidence generation, and execution momentum outweigh the manageable risks and uncertainties.Company Guidance
Strong Net Revenue Growth
Q2 net revenue of $57.5M, up 17% year-over-year and 11% quarter-over-quarter; first half 2026 net revenue grew ~24% versus the same period in 2025. Company expects to land at the mid- to high-end of full year 2026 RYTELO net product revenue guidance of $220M–$240M.
Demand and Account Expansion
Third consecutive quarter of demand growth with 5% demand growth in Q2 versus Q1 and an 8% increase in prescribing accounts, expanding footprint to ~1,575 accounts since launch. First- and second-line patient starts on a rolling 12-month basis were 34%.
Operational Efficiency and Expense Discipline
Through H1 2026 total operating expenses decreased ~4% year-over-year while net revenue increased ~24%, demonstrating improved operating leverage. Q2 operating expenses (ex-Cogs) were $60.7M, roughly flat to prior-year quarter ($60.3M) as higher commercial and CMC investments were offset by lower headcount costs.
Strong Balance Sheet and Cash Position
Cash, cash equivalents, restricted cash and marketable securities of approximately $327M at June 30, 2026, providing financial flexibility to fund commercial investments, ongoing clinical programs and opportunistic innovation.
Scientific Progress and Real-World Evidence
Presented first real-world evidence study of RYTELO in lower-risk MDS at EHA with findings generally consistent with Phase III IMerge. Additional data (including updated IMbark OS analysis) reinforce IMtelestat scientific rationale and support overall survival as the primary endpoint for Phase III IMpactMF.
Strategic Commercial Execution and Leadership Hire
Refocused commercial strategy (targeting high-volume community centers, earlier patient identification, account management and omnichannel engagement) showing traction. Appointment of Chinmaya Rath as Chief Business Officer to drive BD/strategic growth.
DE:GON Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed